ZAMBELLI, ALBERTO
ZAMBELLI, ALBERTO
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
2024 Cazzaniga, M; Pronzato, P; Amoroso, D; Bernardo, A; Biganzoli, L; Bisagni, G; Blasi, L; Bria, E; Cognetti, F; Crinò, L; De Laurentiis, M; Del Mastro, L; De Placido, S; Beano, A; Ferraù, F; Foladore, S; Forcignanò, R; Gamucci, T; Garrone, O; Gennari, A; Giordano, M; Giotta, F; Giovanardi, F; Latini, L; Livi, L; Marchetti, P; Mattioli, R; Michelotti, A; Montemurro, F; Putzu, C; Riccardi, F; Ricciardi, G; Romagnoli, E; Sarobba, G; Spazzapan, S; Tagliaferri, P; Tinari, N; Tonini, G; Turletti, A; Verusio, C; Zambelli, A; Mustacchi, G
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
2023 Zambelli, A; Cazzaniga, M; La Verde, N; Munzone, E; Antonazzo, I; Mantovani, L; Di Cosimo, S; Mancuso, A; Generali, D; Cortesi, P
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial
2023 Malorni, L; Bianchini, G; Caputo, R; Zambelli, A; Puglisi, F; Bianchi, G; Del Mastro, L; Paris, I; Montemurro, F; Allegrini, G; Colleoni, M; Tamberi, S; Zamagni, C; Cazzaniga, M; Orditura, M; Guarneri, V; Castelletti, D; Benelli, M; Di Marino, M; Arpino, G; De Laurentiis, M
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence
2023 Zambelli, A; Gallerani, E; Garrone, O; Pedersini, R; Rota Caremoli, E; Sagrada, P; Sala, E; Cazzaniga, M
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
2020 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Valerio, M; Airoldi, M; Moretti, G; Ficorella, C; Gianni, L; Michelotti, A; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; De Laurentiis, M; Atzori, F; Turletti, A; Porpiglia, M; Santini, D; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Giordano, M; Donadio, M; Biganzoli, L; Del Mastro, L; Bisagni, G; Livi, L; Natoli, C; Montemurro, F; Riccardi, F; Romagnoli, E; Marchetti, P; Torri, V; Pronzato, P; Mustacchi, G
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)
2018 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Valerio, M; Airoldi, M; Moretti, G; Ficorella, C; Arcangeli, V; Diodati, L; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; Piezzo, M; Atzori, F; Turletti, A; Benedetto, C; Cursano, M; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Torri, V
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874)
2018 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Valerio, M; Airoldi, M; Moretti, G; Ficorella, C; Arcangeli, V; Diodati, L; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; Piezzo, M; Atzori, F; Turletti, A; Benedetto, C; Cursano, M; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Torri, V
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study
2018 Cazzaniga, M; Verusio, C; Ciccarese, M; Fumagalli, A; Sartori, D; Ancona, C; Airoldi, M; Moretti, G; Ficorella, C; Arcangeli, V; Diodati, L; Zambelli, A; Febbraro, A; Generali, D; Pistelli, M; Garrone, O; Musolino, A; Vici, P; Maur, M; Mentuccia, L; La Verde, N; Bianchi, G; Artale, S; Blasi, L; Piezzo, M; Atzori, F; Turletti, A; Benedetto, C; Cursano, M; Fabi, A; Gebbia, V; Schirone, A; Palumbo, R; Ferzi, A; Frassoldati, A; Scavelli, C; Clivio, L; Torri, V; On behalf of The EVA Study, G
Management and Survival of Pleural Mesothelioma: A Record Linkage Study
2018 Carioli, G; Bonifazi, M; Rossi, M; Zambelli, A; Franchi, M; Zocchetti, C; Gasparini, S; Corrao, G; La Vecchia, C; Negri, E
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction
2018 Caleca, L; Catucci, I; Figlioli, G; De Cecco, L; Pesaran, T; Ward, M; Volorio, S; Falanga, A; Marchetti, M; Iascone, M; Tondini, C; Zambelli, A; Azzollini, J; Manoukian, S; Radice, P; Peterlongo, P
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
2017 Romano, M; della Porta, M; Gallì, A; Panini, N; Licandro, S; Bello, E; Craparotta, I; Rosti, V; Bonetti, E; Tancredi, R; Rossi, M; Mannarino, L; Marchini, S; Porcu, L; Galmarini, C; Zambelli, A; Zecca, M; Locatelli, F; Cazzola, M; Biondi, A; Rambaldi, A; Allavena, P; Erba, E; D'Incalci, M
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017 Cicchiello, F; Riva, F; Cazzaniga, M; Pedani, F; Nicolini, M; Butti, C; Liscia, N; Pogliani, C; Capri, G; Alu, M; Febbraro, A; Petrucelli, L; D'Onofrio, L; De Laurentiis, M; Pellegrini, D; Mentuccia, L; Cocciolone, V; Miraglio, E; Bajardi, E; Dester, M; Paterno, E; Guaitoli, G; Ferrarini, I; Gervasi, E; Licata, L; Benedetto, C; Andreis, D; Bordin, E; Ancona, C; Pizzuti, L; Fotia, V; Berardi, R; Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, G; Blasi, L; Campidoglio, S; Ciccarese, M; Cursano, M; Piezzo, M; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Turletti, A; Valerio, M; Vici, P; Zambelli, A; Clivio, L; Torri, V
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival
2016 Rossi, M; Carioli, G; Bonifazi, M; Zambelli, A; Franchi, M; Moja, L; Zambon, A; Corrao, G; La Vecchia, C; Zocchetti, C; Negri, E
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study
2015 Beltrame, L; Di Marino, M; Fruscio, R; Calura, E; Chapman, B; Clivio, L; Sina, F; Mele, C; Iatropoulos, P; Grassi, T; Fotia, V; Romualdi, C; Martini, P; Noris, M; Paracchini, L; Craparotta, I; Petrillo, M; Milani, R; Perego, P; Ravaggi, A; Zambelli, A; Ronchetti, E; D'Incalci, M; Marchini, S
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study
2014 Negri, E; Zambelli, A; Franchi, M; Rossi, M; Bonifazi, M; Corrao, G; Moja, L; Zocchetti, C; La Vecchia, C
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
2014 Bonifazi, M; Franchi, M; Rossi, M; Zambelli, A; Moja, L; Zambon, A; Corrao, G; La Vecchia, C; Zocchetti, C; Negri, E
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients
2013 Moccia, F; Lodola, F; Dragoni, S; Cattaneo, F; Tancredi, R; Bottino, C; Laforenza, U; Guerra, G; Zambelli, A; Rosti, V; DELLA PORTA, M; Tanzi, F
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
2013 Marchini, S; Fruscio, R; Clivio, L; Beltrame, L; Porcu, L; Nerini, I; Cavalieri, D; Chiorino, G; Cattoretti, G; Mangioni, C; Milani, R; Torri, V; Romualdi, C; Zambelli, A; Romano, M; Signorelli, M; Giandomenico, S; D'Incalci, M
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study
2013 Bonifazi, M; Franchi, M; Rossi, M; Moja, L; Zambelli, A; Zambon, A; Corrao, G; La Vecchia, C; Zocchetti, C; Negri, E